Join Us in Changing Lives At OXB, our people are at the heart of everything we do. We’re on a mission to enable life-changing therapies to reach patients around the world—and we’re looking for passionate individuals who embody our core values every day: Responsible, Responsive, Resilient, and Respectful. We are currently recruiting for a Client Program Manager to join the team. The purpose of this role is to manage the relationship between OXB and its Clients and ensure projects are delivered on time and within budget to the required quality to ensure successful long-term alliances. OXB’s Client Programme Management team ensure delivery of Process Development and Manufacturing technical projects for our customers. We are happy to consider applications from aspiring Client Project Managers with proven competency of delivering on Client Projects within this field. We are also able to consider flexible home working arrangements combined with some on-site presence. Your responsibilities in this role would be: • Maintains client / partner satisfaction to ensure successful long-term alliances. • Understands client needs and identifies ongoing project opportunities. • Ensures projects are delivered within the agreed scope, timeline and budget and project milestones are met. • Ensures project risks are identified and effective mitigation actions are put in place. • Provides project updates and performance data to OXB (Oxford Biomedica) Management to enable effective strategic and tactical decision making. • Responsible for all financial aspects of the collaboration including forecasting, cost control etc. • Determines scope, costings, and timelines for new work packages. • Assists with preparing proposals and contributes to contract negotiations for prospective clients. We are looking for: • Scientific Degree or PhD • Project Management qualification preferred. • Demonstrable experience using Project Management tools, methodologies & techniques. • Significant project management experience inclusive of budgetary ownership, preferably within the pharmaceutical /biotech industry. • Good technical understanding of biopharmaceutical process development and manufacturing. • Experience of working to external client deliverables. • Line management experience preferred but not essential. • Experience of managing projects using MS Project & MS Excel. About Us: OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXB’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise. Why Join Us? • Competitive total reward packages • Wellbeing programmes that support your mental and physical health • Career development opportunities to help you grow and thrive • Supportive, inclusive, and collaborative culture • State-of-the-art labs and manufacturing facilities • A company that lives its values: Responsible, Responsive, Resilient, Respect We want you to feel inspired every day. At OXB, we’re future-focused and growing fast. We succeed together—through passion, commitment, and teamwork. Ready to Make a Difference? Collaborate. Contribute. Change lives. Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.